Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
884 results about "Drug screens" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Targets for therapeutic intervention identified in the mitochondrial proteome
Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences [SEQ ID NOS:1-3025] of polypeptides that comprise the human heart mitochondrial proteome are provided, using fractionated proteins derived from highly purified mitochondrial preparations, to identify previously unrecognized mitochondrial molecular components.
Owner:THE BUCK INST FOR RES ON AGING +1
Microfluidic particle-analysis systems
ActiveUS7312085B2Bioreactor/fermenter combinationsBiological substance pretreatmentsReady to useMixed group
The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.
Owner:STANDARD BIOTOOLS INC
Microfluidic particle-analysis systems
InactiveUS20100120077A1Bioreactor/fermenter combinationsBiological substance pretreatmentsAssayMixed group
The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.
Owner:STANDARD BIOTOOLS INC
Microfluidic particle-analysis systems
InactiveUS7452726B2Bioreactor/fermenter combinationsBiological substance pretreatmentsMixed groupScale down
The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.
Owner:FLUIDIGM CORP
Device for optical monitoring of constituent in tissue or body fluid sample using wavelength modulation spectroscopy, such as for blood glucose levels
InactiveUS7356364B1Improve signal-to-noise ratioReduce calculationMedical devicesCatheterConcentrations glucosePhotodetector
A device for monitoring the concentration level of a constituent in tissue or a body fluid sample, such as glucose concentration in blood, has a laser light source which is modulated about a center emission frequency to probe the absorption spectrum of the constituent being monitored, a laser driver circuit for tuning and modulating the laser light, a photodetector for detecting light from the laser light source transmitted through the sample as the modulation frequency of the laser is tuned, and a demodulator for demodulating the transmitted light and detecting variations in magnitude at harmonics of the modulation frequency to assess the concentration level of that constituent. The device utilizes short-wavelength near-infrared laser light to monitor blood glucose levels, and could also be used for drug screening and diagnosis of other medical conditions as well. In one embodiment, the device is used to monitor blood glucose level externally from the body and non-invasively by trans-illumination through a thin layer of skin, without the need for physical penetration of the skin. In another embodiment, the device is used as an intravenous sensor deployed through a catheter, and its output can be used to control an insulin pump to stabilize the patient's blood glucose levels.
Owner:UNIV OF HAWAII
Therapeutic applications of pro-apoptotic benzodiazepines
Benzodiazepinc compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures (I) or (II): wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.
Owner:RGT UNIV OF MICHIGAN
Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
ActiveUS20060280733A1Low toxicityNervous disorderPeptide/protein ingredientsHigh molecular massAmyloid disease
Compositions of matter that comprise one or more conformational epitopes found on amyloid peptide aggregates, antibodies to such epitopes and methods for making and using the compositions, eptitopes and / or antibodies. The invention includes synthetic or isolated compositions that contain or consist of certain conformational epitopes that are found on peptide aggregates (e.g., toxic peptide aggregates) present in human or veterinary patients who suffer from, or who are likely to develop, amyloid diseases (e.g., Alzheimer's Disease). The invention includes methods for the detection, treatment and prevention of diseases in humans or animals, using such compositions. The invention further includes antibodies which bind to the conformational epitopes as well as methods for making such antibodies and methods for the detection, treatment and prevention of diseases and / or identification of potential therapies (e.g., drug screening) using such antibodies.
Owner:RGT UNIV OF CALIFORNIA
Microfluidic particle-analysis systems
InactiveUS8658418B2Bioreactor/fermenter combinationsBiological substance pretreatmentsAssayMixed group
Owner:STANDARD BIOTOOLS INC
Methods of identifying compounds that modulate body weight using the OB receptor
The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and / or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.
Owner:MILLENNIUM PHARMA INC
Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potentatial of a cancer thereof
InactiveUS20030206901A1Quick checkRapid isolationSolvent extractionOther blood circulation devicesCancer cellProteinase activity
The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)]expressed on the surface of metastasizing cancer cells.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Culture media for stem cells
Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.
Owner:KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN
One-dimensional biological chip and application in gene, protein expression analysis
Disclosed is an one-dimensional biochip belonging to a serial analytic technique for micro-total analysis systems. The one-dimensional biochip is provided with a plurality of cellules on the micro-separation channel of micro flow control chip, microparticles modified by different biomolecules on surface are arranged in different cellules; in the gene or protein analysis, when the sample flows through the microchannel with a plurality of cellules, the microparticles can specifically identify and capture multiple target molecules, then a reagent with fluorescence labels can be introduced, and finally the microparticles will specifically combine with the fluorescence labels on surface to be detected by fluorescent imaging. The one-dimensional biochip provided by the invention not only has advantages of micro flow control technology and array analysis, but also improves the detection sensitivity and identification capability of target molecules, and provides an effective research measure for the gene and protein expression analysis at single cell level, and tumor research and drug screening.
Owner:HUNAN UNIV
Synthesis of cyclic peptides
InactiveUS7589170B1Facilitate cyclisation reactionImprove responseNervous disorderAntipyreticCyclic peptideSolid-phase synthesis
This invention relates to methods for preparing cyclic peptides and peptidomimetic compounds in solution and bound to solid supports, and to cyclic peptide or peptidomimetic libraries for use in drug screening programs. In particular, the invention relates to a generic strategy for synthesis of cyclic peptides or peptidomimetics that enables the efficient synthesis under mild conditions of a wide variety of desired compounds. Two approaches were evaluated for their improvements in solution and solid phase synthesis of small cyclic peptides: positioning reversible N-amide substituents in the sequence; and applying native ligation chemistry in an intramolecular sense. Systematic investigation of the effects of preorganising peptides prior to cyclisation by using peptide cyclisation auxiliaries, and developing new linkers and peptide cyclisation auxiliaries to aid cyclic peptide synthesis gives surprising improvements in both yields and purity of products compared to the prior art methods. The combination of these technologies provides a powerful generic approach for the solution and solid phase synthesis of small cyclic peptides. The ring contraction and N-amide substitution technology of the invention provide improved methods for the synthesis of cyclic peptides and peptidomimetics. When used in conjunction with linker strategies, this combination provides solid-phase avenues to cyclic peptides and peptidomimetics.
Owner:QUEENSLAND THE UNIV OF
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
A system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein.
Owner:BLUELIGHT THERAPEUTICS INC
Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
ActiveUS20160115448A1Increase differentiationEfficient inductionNervous system cellsArtificial cell constructsProgenitorCholinergic cells
Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1
Drug Screen and Treatment Method
InactiveUS20080221074A1Treat and ameliorate metabolic disorderTreat or ameliorate a metabolic disorderOrganic active ingredientsMicrobiological testing/measurementAcute hyperglycaemiaMedicine
The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.
Owner:NEURMEDIX +2
Simple green synthesis method of nitrogen-doped carbon quantum dots
ActiveCN103788944ASimple methodEasy to operateLuminescent compositionsQuantum yieldUltraviolet lights
The invention discloses a simple green synthesis method of nitrogen-doped carbon quantum dots. Konjac flour, serving as a carbon source, is subjected to pyrolysis in air and solvent extraction to obtain the nitrogen-doped carbon quantum dots. The synthesized nitrogen-doped carbon quantum dots are easily dissolved in solvents such as ethanol, N,N-dimethyl formamide and dimethyl sulfoxide and can be ultrasonically dispersed in water, the particle size is 0.3-2.4 nm, the highest fluorescence quantum yield is 22%, and the yield is 3%-5%. The nitrogen-doped carbon quantum dots can emit blue light, green light and red light respectively under the excitation of ultraviolet light, blue light and green light, and the fluorescence property of the nitrogen-doped carbon quantum dots can be adjusted through the excitation light wavelength, concentration and pH value. The method is simple and easy to operate and can be applied to large-scale synthesis of carbon quantum dots while the cost is low. The synthesized nitrogen-doped carbon quantum dots can be applied to the development of living cells in vitro and the preparation of stimulus response materials, and have broad application prospects in multiple fields of biomarkers, biomedical imaging, bio-development, drug screening and detection, biochips, biosensing and the like.
Owner:ANHUI UNIVERSITY
Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
InactiveUS20020150885A1Microbiological testing/measurementChemiluminescene/bioluminescenceScreening proceduresApoptosis
The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
Owner:CYTOVIA INC
Method for separating and extracting Milkvetch Root
InactiveCN101073592AOrganic compounds purification/separation/stabilisationSugar derivativesChemical compositionMedicine
The invention is concerned with the standard extraction and isolation method of Astragalus root. It can form a medicinal materials component store according to different polarity levels of the Astragalus root divide into several groups, which each group contents few types of compound. It can use to discover new medicine by conducting drug screening from the component store. The method can reduce the period of medicine extraction and isolation, and reduce the consumption of manpower and material resources, and it suits for most types of medicine.
Owner:TIANJIN TASLY PHARMA CO LTD
Identification of essential genes of cryptococcus neoformans and methods of use
InactiveUS20040014955A1Simple and reasonable designSugar derivativesMicrobiological testing/measurementBiotechnologyVirulent characteristics
The present invention provides C. neoformans genes that are essential and are potential targets for drug screening. The nucleotide sequence of the target genes can be used for various drug discovery purposes, such as expression of the recombinant protein, hybridization assay and construction of nucleic acid arrays. The uses of proteins encoded by the essential genes, and genetically engineered cells comprising modified alleles of essential genes in various screening methods are also encompassed by the invention. The present invention also provides methods and compositions that enable the experimental determination as to whether any gene in the genome of Cryptococcus neoformans is essential, and whether that gene is required for virulence or pathogenicity. The identification of essential genes and those genes critical to the development of virulent infections, provides a basis for the development of screens for new drugs against C. neoformans.
Owner:MERCK & CO INC
Receptor(SSTR4)-selective somatostatin analogs
Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA1,2,4,5,12,13[Ala7]-SRIF; des-AA1,2,4,5,12,13[Aph7]-SRIF, des-AA1,2,4,5,12,13[Aph7]Cbm-SRIF; des-AA1,2,4,5,12,13[Tyr2,Ala7]-Cbm-SRIF, and des-AA1,2,4,5,12,13[Tyr7,CβMe-L-2Nal8]-SRIF, and counterparts incorporating D-Cys3 and / or D-Trp8 and / or Ala11, bind with high affinity to the cloned human receptor SSTR4 and activate the receptor, but they do not bind with significant affinity to human SSTR1, SSTR2, SSTR3 or SSTR5. By incorporating an iodinated tyrosine in position-2 in these SSTR4-selective SRIF analogs, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, cytotoxins or highly radioactive elements can be N-terminally coupled or complexed thereto.
Owner:SALK INST FOR BIOLOGICAL STUDIES
Method for obtaining hemopoietic stem cell by using three-dimensional induction system
ActiveCN103937743ABlood/immune system cellsCell culture active agentsInduced pluripotent stem cellBone marrow cell
The invention provides a method for obtaining a hemopoietic stem cell by using a three-dimensional induction system. A three-dimensional cell culture medium or cell culture bracket, such as a three-dimensional cell culture system made of the materials such as hydrogel, seaweed and the like is utilized, and / or combined with matrix cells such as bone marrow cell, mouse bone marrow cell lines OP9, OP9DL1 and the like, and / or combined with a plurality of factors including mesoderm induction factors, hematopoietic growth factor and the like to induce multipotent stem cells to differentiate into hemopoietic stem cells. A new method for obtaining the hemopoietic stem cells is built. The system for efficiently inducing the multipotent stem cells to differentiate into the hemopoietic stem cells by using a three-dimensional induction system and / or combining with matrix cells such as bone marrow cell and the like and / or a plurality of factors is built for the first time. Theoretical basis and a technology platform are provided for obtaining clinically available hemopoietic stem cells, and a new method and a new concept are developed for application of hematopoietic cells derived from multipotent stem cells in the fields such as disease mechanism exploration, drug screening and the like.
Owner:ZHEJIANG UNIV
Human brain glioma cell line, and establishing method and application thereof
ActiveCN103627673AStable traitsStrong scientific research informationMicrobiological testing/measurementTumor/cancer cellsHuman gliomaIn vivo
The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.
Owner:SHANGHAI CHEMPARTNER CO LTD +1
Automated high-content live animal drug screening using c. elegans
ActiveUS20110154510A1High contentHigh throughput screenCompounds screening/testingCompound screeningDrugBiology
Owner:UNIVERSITY OF PITTSBURGH
Antineoplastic drug evaluation and screening method based on cell microscopic image information
InactiveCN101149327ARealize program controlRealize control program controlMicrobiological testing/measurementIndividual particle analysisMicroscopic imageFluorescence
The invention provides the appraisal and selective method for the antineoplastic drug based on the cell micrograph information, which uses a sort of selection and appraisal hardware system to appraisal and select the antineoplastic drug by different fluorescence dye marking and measuring the multicellular parameter change in cell. The hardware system is made up of the high precision electric hydrous platform, the fluorescence vision system, the image collecting and processing system and working station. The diacetoxyl fluoresceine dyeing measures the active cell number; the double dyeing method of Hoechst33342 and iodized pyridine appraise the drug inducing the cell die; the three dyeing method of FDA, Hoechst33342 and PI analyzes the die mode induced by drug. The invention can measure at least two kinds of single cell or cell subgroup which expresses different drone cell organ. The method is in reason and can be used in study of drug action mechanism and selecting the high hedonic drug and toxicity analyzing, which can be used in selecting drug and appraising the drug toxicity.
Owner:ZHEJIANG UNIV
Synthesis of methotrexate-containing heterodimeric molecules
InactiveUS7230101B1Improve membrane permeabilityEffective isolationBiocideOrganic chemistryProtein targetCombinatorial chemistry
The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target. In certain embodiments, the invention contemplates the synthesis of the following methotrexate-containing heterodimeric probe:
Owner:AGGENIX
Method for directionally differentiating multipotential stem cell in vitro into myocardial cell
ActiveCN104293730AMany connectionsDecreased frequency of calcium wavesVertebrate cellsArtificial cell constructsGerm layerHeart development
The invention provides a method for directionally differentiating a multipotential stem cell in vitro into a myocardial cell and provides a culture medium for establishing myocardial cell differentiation by means of induction in vitro under a three-dimensional suspension condition. The culture medium comprises a differential medium for induced differentiation of a multipotential stem cell into a precursor cell of mesoblast, a differential medium for differentiating the precursor cell of mesoblast into the myocardial cell and a long-term maintaining culture medium of the myocardial cell. The method provided by the invention is simple and reliable, low in cost, stable and efficient and high in safety. By adopting a suspension culture system, high-quality myocardial cells can be industrially produced without any subsequent screening and purifying steps, can be directly used for application demands of scientific research of heart development, cell therapy of heart diseases, transplanting due to cardiac trauma and drug screening, and has inestimable scientific, social and economical benefits.
Owner:昆明圆梦生命科学研究院有限公司
Stochastic method to determine, in silico, the drug like character of molecules
InactiveUS20070156343A1Shorten the timeSave moneyChemical property predictionCompound screeningHigh-Throughput Screening MethodsStochastic algorithms
A stochastic algorithm has been developed for predicting the drug-likeness of molecules. It is based on optimization of ranges for a set of descriptors. Lipinski's “rule-of-5”, which takes into account molecular weight, logP, and the number of hydrogen bond donor and acceptor groups for determining bioavailability, was previously unable to distinguish between drugs and non-drugs with its original set of ranges. The present invention demonstrates the predictive power of the stochastic approach to differentiate between drugs and non-drugs using only the same four descriptors of Lipinski, but modifying their ranges. However, there are better sets of 4 descriptors to differentiate between drugs and non-drugs, as many other sets of descriptors were obtained by the stochastic algorithm with more predictive power to differentiate between databases (drugs and non-drugs). A set of optimized ranges constitutes a “filter”. In addition to the “best” filter, additional filters (composed of different sets of descriptors) are used that allow a new definition of “drug-like” character by combining them into a “drug like index” or DLI. In addition to producing a DLI (drug-like index), which permits discrimination between populations of drug-like and non-drug-like molecules, the present invention may be extended to be combined with other known drug screening or optimizing methods, including but not limited to, high-throughput screening, combinatorial chemistry, scaffold prioritization and docking.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Single cell sensor for ectocytic action potential detection and its preparing method
InactiveCN1554942AImprove accuracy and stabilityCell attachment and growth are in good conditionMaterial analysis by electric/magnetic meansPhysicsAction potential
The single cell sensor for ectocytic action potential measurement is developed on the basis of multiple light source cell micro physiological gauge, and has light addressing potential sensor without limitation in cell culture and light source moving addressing capable of tracking and positioning randomly cultured single cell for measurement. The present invention has also improved light source system with raised precision and stability for locating the measurement in single cell or even in single ion passage, so as to measure precisely the action and action target point of medicine on single cell. The single cell sensor can realize the fast real-time monitoring of outer action potential of nerve cell and the qualitative analysis of cell excitation and inhibition of different medicine in different concentration, and is used mainly in medicine screening, analysis and estimation.
Owner:ZHEJIANG UNIV
Gene disruption methodologies for drug target discovery
The present invention provides methods and compositions that enable the experimental determination as to whether any gene in the genome of a diploid pathogenic organism is essential, and whether it is required for virulence or pathogenicity. The methods involve the construction of genetic mutants in which one allele of a specific gene is inactivated while the other allele of the gene is placed under conditional expression. The identification of essential genes and those genes critical to the development of virulent infections, provides a basis for the development of screens for new drugs against such pathogenic organisms. The present invention further provides Candida albicans genes that are demonstrated to be essential and are potential targets for drug screening. The nucleotide sequence of the target genes can be used for various drug discovery purposes, such as expression of the recombinant protein, hybridization assay and construction of nucleic acid arrays. The uses of proteins encoded by the essential genes, and genetically engineered cells comprising modified alleles of essential genes in various screening methods are also encompassed by the invention.
Owner:MERCK & CO INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com